Friday, September 16, 2016

UPDATE 2-Novo plans larger study after encouraging semaglutide results

COPENHAGEN, Sept 16 (Reuters) - Novo Nordisk's

experimental injectable diabetes drug semaglutide reduced

cardiovascular risk by 26 percent, according to results released

on Friday, paving the way...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)